Table III.

Treatment‐Emergent Adverse Events Reported in >5% of Patients in Any Group

	Placebo (n=50)		Eplerenone 50 mg (n=49)		Eplerenone 100 mg (n=46)		Eplerenone 200 mg (n=48)
Adverse Event	n	%	n	%	n	%	n	%
Influenza‐like symptoms	3	6.0	4	8.2	3	6.5	6	12.5
AST increased	1	2.0	2	4.1	0	0.0	4	8.3
ALT increased	0	0.0	3	6.1	0	0.0	4	8.3
Eosinophilia	0	0.0	1	2.0	1	2.2	4	8.3
GGT increased	0	0.0	1	2.0	2	4.3	3	6.3
Back pain	1	2.0	1	2.0	0	0.0	3	6.3
Headache	6	12.0	8	16.3	1	2.2	2	4.2
Hypertriglyceridemia	3	6.0	2	4.1	2	4.3	2	4.2
Hyperuricemia	1	2.0	3	6.1	3	6.5	2	4.2
Pharyngitis	1	2.0	2	4.1	3	6.5	2	4.2
Malaise	3	6.0	0	0.0	1	2.2	1	2.1
Upper RTI	3	6.0	2	4.1	1	2.2	1	2.1
Lymphocytosis	3	6.0	1	2.0	1	2.2	0	0.0
Specific ECG abnormality	3	6.0	0	0.0	1	2.2	0	0.0
Hypertension aggravated	3	6.0	2	4.1	0	0.0	0	0.0
Peripheral pain	3	6.0	0	0.0	0	0.0	0	0.0
AST=aspartate transaminase; ALT=alanine transaminase; GGT=γ‐glutamyl transferase; RTI=respiratory tract infection; ECG=electrocardiogram